Keudell Morrison Wealth Management Acquires 126 Shares of argenx SE (NASDAQ:ARGX)

Keudell Morrison Wealth Management lifted its holdings in argenx SE (NASDAQ:ARGX) by 33.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 507 shares of the company’s stock after acquiring an additional 126 shares during the period. Keudell Morrison Wealth Management’s holdings in argenx were worth $312,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ARGX. Stifel Financial Corp lifted its stake in argenx by 15.3% in the third quarter. Stifel Financial Corp now owns 8,832 shares of the company’s stock worth $4,788,000 after purchasing an additional 1,170 shares during the last quarter. FMR LLC grew its position in argenx by 35.9% in the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock valued at $2,598,445,000 after acquiring an additional 1,265,486 shares during the last quarter. Simplify Asset Management Inc. increased its stake in argenx by 64.0% in the third quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company’s stock worth $1,311,000 after purchasing an additional 944 shares during the period. Perpetual Ltd purchased a new stake in shares of argenx during the third quarter valued at $76,314,000. Finally, Westfield Capital Management Co. LP bought a new position in shares of argenx in the third quarter worth about $571,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Guggenheim raised their price target on argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Wells Fargo & Company boosted their price target on argenx from $639.00 to $723.00 and gave the stock an “overweight” rating in a research report on Thursday, December 19th. William Blair raised argenx from a “market perform” rating to an “outperform” rating in a research report on Friday, November 1st. Wedbush restated an “outperform” rating and issued a $655.00 price target on shares of argenx in a report on Tuesday, December 3rd. Finally, Baird R W downgraded shares of argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $658.39.

argenx Price Performance

argenx stock opened at $665.68 on Friday. The company’s fifty day moving average price is $631.59 and its 200 day moving average price is $568.27. argenx SE has a 1 year low of $349.86 and a 1 year high of $678.21.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. During the same quarter in the prior year, the firm earned ($1.25) EPS. On average, sell-side analysts predict that argenx SE will post 2.78 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.